The clinical research of rFVIIa on reducing intraoperative blood loss of severe acute pancreatitis

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-13003895

Enrollment

Unknown

Registered

2013-10-19

Start date

2008-03-06

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

severe acute pancreatitis

Interventions

study group:rVIIa was infused with 40/kg before operation

Control:Placebo

Eligibility

Sex/Gender

All

Age

21 Years to 70 Years

Inclusion criteria

Inclusion criteria: Patients were eligible for the trial if they suffered from SAP and would receive necrosectomy for the first time. SAP was diagnosed by the criteria based on the consensus of the international symposium on AP. The operationindication was local infection around the pancreas. CT scan was performed on the day before the operation day, and the patients whose CT severity index>=6 scores were enrolled.

Exclusion criteria

Exclusion criteria: (1) abdominal or retroperitoneal spontaneous hemorrhage were found before the operation; (2) patients who had a history of blood system diseases, myocardial infarction, and/or thrombosis; (3) patients who received abdominal surgery within the last three months.

Design outcomes

Primary

Measure	Time frame
prothrombin time;activated partial thromboplastin time;blood loss;blood transfusion;operation time;	—

Secondary

Measure	Time frame
ICU stay;mortality;	—

Countries

China

Contacts

Public ContactLi Weiqin

Jiangsu Province Hospital of Traditional Chinese Medicine

liweiqindr@hotmail.com+86 13951839654

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026